| Business Summary | | Akorn,
Inc.
manufactures
and
markets
diagnostic
and
therapeutic
pharmaceuticals
in
specialty
areas
such
as
ophthalmology,
rheumatology,
anesthesia
and
antidotes,
among
others.
The
Company
also
markets
ophthalmic
surgical
instruments
and
related
products.
Customers
include
physicians,
optometrists,
wholesalers,
group
purchasing
organizations
and
other
pharmaceutical
companies.
The
Company
also
provides
contract-manufacturing
services.
Upon
its
acquisition
of
Pasadena
Research
Laboratories,
Inc.,
a
developer
and
distributor
of
injectable
pharmaceutical
products,
in
May
1996,
the
Company
reorganized
its
operations
into
two
segments,
ophthalmic
and
injectable. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Akorn,
Inc.
manufactures
and
markets
diagnostic
and
therapeutic
pharmaceuticals
in
specialty
areas
such
as
ophthalmology,
rheumatology,
anesthesia
and
antidotes,
among
others.
AKRN
also
markets
ophthalmic
surgical
instruments
and
related
products.
For
the
six
months
ended
6/01,
net
sales
fell
52%
to
$16.7
million.
Net
loss
totalled
$19.3
million
vs.
an
income
of
$4
million.
Results
reflect
lower
sales
in
the
opthalmic
segment
and
increases
in
reserves
for
inventory
items. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| John Kapoor, Ph.D., 57 Chairman,
CEO | -- | -- | Antonio Pera Pres,
COO, Director | -- | -- | Kevin Harris, 40 CFO,
VP, Sec., Treasurer | -- | -- | Harold Koch, Jr., 52 Sr.
VP, Bus. Devel. and Planning | $170K | $334K | Shahid Ahmed VP,
Quality Assurance, Quality Control and Regulatory Affairs | -- | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|